Lilly will acquire Verve Therapeutics and a pipeline of one-time treatments for cardiovascular diseases in a deal worth up to US$1.3 billion.

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA approves a new dosing regimen of the drug with an improved safety profile.

More than 450 fans of fashion icon Lilly Pulitzer attended events in Palm Beach, Palm Beach Gardens and West Palm Beach during the June 19-22 event.

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for market share, data from research firm Pharmarack showed on Monday.

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a ...

Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related imaging abnormalities in Alzheimer's treatment. This development comes ...

In other recent news, Eli Lilly has announced its second-quarter earnings report, with Guggenheim raising its price target to $942.00 while maintaining a Buy rating.

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in the category. The brokerage sees long-term growth potential driven by ...

Four senators are investigating partnerships between direct-to-consumer telehealth firms and pharma companies for possible violations of kickback laws.

President Trump has threatened to levy tariffs of up to 200% on pharmaceutical imports. Lilly's margins could be negatively affected if the company absorbs the higher costs. The active ingredients ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving ...

The FDA has approved a label update for Eli Lilly’s Kisunla (donanemab-azbt), introducing a new recommended titration dosing schedule aimed at reducing the incidence of amyloid-related imaging ...